A Study to Evaluate the Diagnostic Efficacy of 68Ga- MY6349 PET/CT in Patients With Tumours

Inclusion Criteria:

• Age ≥ 18 years; Patients with pathologically confirmed tumour and proposed surgicalresection/exploration (including primary or recurrent metastatic tumour); Expectedsurvival > 3 months, as judged by the doctor; Voluntarily sign the informed consentform; willing and able to follow the study protocol

Exclusion Criteria:

• Persons with a known history of hypersensitivity to 68Ga-MY6349 and 68Ga-PSMA or 18F-FDG and their excipients; Those who cannot tolerate intravenous drug deliverymethods (e.g., history of needle and blood sickness); Patients who have receivedanti-tumour therapy before the examination or neoadjuvant chemotherapy/targetedtherapy for tumour reduction after the examination and up to the preoperativeperiod; Pregnant and lactating women; Practitioners who need to be exposed toradioactive conditions for a long time; Serious diseases of heart, kidney, lung,vascular, neurological and psychiatric systems, immunodeficiency diseases andhepatitis/cirrhosis; Have participated in other interventional clinical trialswithin 1 month prior to screening; Patients undergoing chemotherapy, immunotherapyor molecular targeted therapy; Presence of other conditions that, in the opinion ofthe investigator, make participation in this study unsuitable.